Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial

M Kathryn Dahlgren; Kelly A Sagar; Ashley M Lambros; Rosemary T Smith; Staci A Gruber

doi:10.1001/jamapsychiatry.2020.3567

Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial

JAMA Psychiatry. 2021 Mar 1;78(3):335-337. doi: 10.1001/jamapsychiatry.2020.3567.

Authors

M Kathryn Dahlgren^{1

2

3}, Kelly A Sagar^{1

2

3}, Ashley M Lambros^{1

2}, Rosemary T Smith^{1

2}, Staci A Gruber^{1

2

3}

Affiliations

¹ Cognitive and Clinical Neuroimaging Core, McLean Hospital Imaging Center, Belmont, Massachusetts.
² Marijuana Investigations for Neuroscientific Discovery Program, McLean Hospital Imaging Center, Belmont, Massachusetts.
³ Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

Abstract

This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants.

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Cannabidiol / administration & dosage
Cannabidiol / urine*
Cannabinoid Receptor Agonists / administration & dosage
Cannabinoid Receptor Agonists / urine*
Dronabinol / administration & dosage
Dronabinol / urine*
Female
Humans
Male
Substance Abuse Detection*
Urinalysis*

Substances

Cannabinoid Receptor Agonists
Cannabidiol
Dronabinol